Effect of salcatonin given intranasally on early postmenopausal bone loss.
Open accessThe DOI matches its Crossref record.
Abstract
OBJECTIVE--To study the effect of salmon calcitonin (salcatonin) given intranasally on calcium and bone metabolism in early postmenopausal women. DESIGN--Double blind, placebo controlled, randomised group comparison. SETTING--Outpatient clinic for research into osteoporosis. SUBJECTS--52 Healthy women who had had a natural menopause two and a half to five years previously. INTERVENTIONS--The 52 women were allocated randomly to two years of treatment with either salcatonin 100IU given intranasally (n = 26) or placebo (n = 26). Both groups received a calcium supplement of 500 mg daily. Seven of the women receiving salcatonin and six of those receiving placebo left the study before its end. MAIN OUTCOME MEASURES--Bone mineral content in the spine, the total skeleton, and the forearms after two years of treatment. RESULTS--Bone mineral content in the spine was significantly higher in the women who had received salcatonin than in those who had received placebo both after one year and after two years of treatment. After one year the difference was 3.8% (95% confidence interval 0.0 to 7.6%) and after two years it was 8.2% (3.8 to 12.6%). In contrast, the bone mineral content in the distal and proximal forearms and in the total skeleton declined similarly in both groups by about 2% each year, and after two years of treatment the differences between the groups were not significant. Biochemical estimates of bone turnover were not affected by salcatonin. CONCLUSION--The results suggest that salcatonin given intranasally in the dose used prevents bone loss in the spine of early post menopausal women but does not affect the peripheral skeleton.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Papaioannou, A., Morin, S., Cheung, A. M., Atkinson, S., Brown, J. P., Feldman, S., Hanley, D. A., Hodsman, A., Jamal, S. A., Kaiser, S. M., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.100771 · Cited by 1,749
Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122
“Number of participants at risk (n 5 305) (n 5 313) (n 5 315) (n 5 312) All nonvertebral fractures Participants [n (%)] 48 (16) 32 (10) 46 (15) 41 (13) Relative risk (95% CI) — 0.”
The Prevention and Treatment of Osteoporosis
Wood, A. J. J., Riggs, B. L., & Melton, L. J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199208273270908 · Cited by 754
Treatment of postmenopausal osteoporosis
Delmas, P. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08827-x · Cited by 681
Treatment of Postmenopausal Osteoporosis
Eastell, R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803123381107 · Cited by 615
Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin
Sambrook, P., Birmingham, J., Kelly, P., Kempler, S., Nguyen, T., Pocock, N., & Eisman, J. (1993) · New England Journal of Medicine · doi:10.1056/nejm199306173282404 · Cited by 520
Prevention and Management of Osteoporosis: Current Trends and Future Prospects
Compston, J. E. (1997) · Drugs · doi:10.2165/00003495-199753050-00001 · Cited by 487
Overgaard, K., Hansen, M. A., Jensen, S. B., & Christiansen, C. (1992) · BMJ · doi:10.1136/bmj.305.6853.556 · Cited by 426
Self-citationAssociation of osteoporotic vertebral compression fractures with impaired functional status
Lyles, K. W., Gold, D. T., Shipp, K. M., Pieper, C. F., Martinez, S., & Mulhausen, P. L. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90210-g · Cited by 423
Osteoporosis in elderly: prevention and treatment
Srivastava, M., & Deal, C. (2002) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(02)00022-8 · Cited by 309
VI. Meta-Analysis of Calcitonin for the Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Zytaruk, N., Robinson, V., Weaver, B., Shea, B., Wells, G., Adachi, J., Waldegger, L., Guyatt, G., et al. (2002) · Endocrine Reviews · doi:10.1210/er.2001-6002 · Cited by 286
Salmon calcitonin: a review of current and future therapeutic indications
Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0490-1 · Cited by 216
“Studies in early menopausal women have typically shown a stabilization of BMD at the lumbar spine [46, 47].”
BackgroundSalmon Calcitonin Use and Associated Cancer Risk
Overman, R. A., Borse, M., & Gourlay, M. L. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013509233 · Cited by 96
Cardona, J. M., & Pastor, E. (1997) · Osteoporosis International · doi:10.1007/bf01622285 · Cited by 53
Salmon calcitonin in the prevention of bone loss at perimenopause
Arnala, I. (1996) · Bone · doi:10.1016/8756-3282(96)00084-1 · Cited by 40
Metadata
- Authors
- Overgaard, K., Riis, B. J., Christiansen, C., & Hansen, M. A.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 1989-08-19
- Volume
- 299
- Issue
- 6697
- Pages
- 477-479
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2040874005
- Cited by
- 179
- References
- 0
- FWCI
- 16.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.